MARKET

RCKT

RCKT

Rocket Pharmaceu
NASDAQ
23.42
+0.09
+0.39%
After Hours: 23.42 0 0.00% 16:20 12/01 EST
OPEN
23.20
PREV CLOSE
23.33
HIGH
23.46
LOW
22.57
VOLUME
805.48K
TURNOVER
0
52 WEEK HIGH
24.74
52 WEEK LOW
14.89
MARKET CAP
2.11B
P/E (TTM)
-7.3803
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at RCKT last week (1120-1124)?
Weekly Report · 5d ago
These Six Clinical-Stage Biotech Stocks Are Developing Promising Treatments for Hard-to-Treat Diseases
NASDAQ · 11/20 19:20
Weekly Report: what happened at RCKT last week (1113-1117)?
Weekly Report · 11/20 11:06
Rocket (RCKT) Surges 40% in 3 Months on Regulatory Updates
NASDAQ · 11/15 16:17
Weekly Report: what happened at RCKT last week (1106-1110)?
Weekly Report · 11/13 10:59
Wall Street Analysts See a 167.09% Upside in Rocket Pharmaceuticals (RCKT): Can the Stock Really Move This High?
NASDAQ · 11/09 14:55
Positive 3Q Results and Robust Financial Position Drive Buy Rating for Rocket Pharmaceuticals with Increased 2024 Price Target
TipRanks · 11/08 12:42
Rocket Pharmaceu: Quarterly report
Press release · 11/08 06:03
More
About RCKT
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders. The Company's clinical programs using lentiviral vector (LVV)-based gene therapy are for the treatment of Fanconi Anemia (FA), a genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe paediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, and Pyruvate Kinase Deficiency (PKD), a rare, monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia. The Company's first clinical program using adeno-associated virus (AAV)-based gene therapy is for Danon Disease, a pediatric heart failure condition. It also has a preclinical AAV-based gene therapy program in PKP2-arrhythmogenic cardiomyopathy (ACM) and BAG3-associated dilated cardiomyopathy (DCM).

Webull offers Rocket Pharmaceuticals Inc stock information, including NASDAQ: RCKT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RCKT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RCKT stock methods without spending real money on the virtual paper trading platform.